PF-05089771

PF-05089771
Legal status
Legal status	Investigational New Medicine;
Identifiers
	IUPAC name 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide;
CAS Number	1235403-62-9
PubChem (CID)	46840946
ChemSpider	29411106
ChEMBL	CHEMBL2325014
Chemical and physical data
Formula	C18H12Cl2FN5O3S2
Molar mass	500.34 g·mol−1
3D model (Jmol)	Interactive image
	SMILES C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F ;
	InChI InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25) ; Key:ZYSCOUXLBXGGIM-UHFFFAOYSA-N ;

PF-05089771 is a selective, small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.^[1]^[2]^[3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.^[4]

References[edit]

^ McMahon, Stephen B.; Koltzenburg, Martin; Tracey, Irene; Turk, Dennis (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 0702053740.
^ Martz, Lauren (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662.
^ Alexandrou, Aristos J.; Brown, Adam R.; Chapman, Mark L.; Estacion, Mark; Turner, Jamie; Mis, Malgorzata A.; Wilbrey, Anna; Payne, Elizabeth C.; Gutteridge, Alex; Cox, Peter J.; Doyle, Rachel; Printzenhoff, David; Lin, Zhixin; Marron, Brian E.; West, Christopher; Swain, Nigel A.; Storer, R. Ian; Stupple, Paul A.; Castle, Neil A.; Hounshell, James A.; Rivara, Mirko; Randall, Andrew; Dib-Hajj, Sulayman D.; Krafte, Douglas; Waxman, Stephen G.; Patel, Manoj K.; Butt, Richard P.; Stevens, Edward B. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4): e0152405. doi:10.1371/journal.pone.0152405. ISSN 1932-6203. PMC 4822888. PMID 27050761.
^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Storer, R. Ian; Swain, Nigel A. (15 August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Legal status

Legal status	Investigational New Medicine
Identifiers
IUPAC name 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide
CAS Number	1235403-62-9
PubChem (CID)	46840946
ChemSpider	29411106
ChEMBL	CHEMBL2325014
Chemical and physical data
Formula	C₁₈H₁₂Cl₂FN₅O₃S₂
Molar mass	500.34 g·mol⁻¹
3D model (Jmol)	Interactive image
SMILES C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
InChI InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25) Key:ZYSCOUXLBXGGIM-UHFFFAOYSA-N